Scrambled siNA GFP Lentivirus
To Order Contact us: lieven@wlsolutions.be
Scrambled sgRNA CRISPR Lentivector |
||
| K018 | 1.0 ug | EUR 184.8 |
ZIP (SCRAMBLED) |
||
| A8830-1 | 1 mg | EUR 74 |
|
Description: PKMζ inhibitor |
||
PADRE scrambled |
||
| SB084 | 1 | EUR 81.81 |
|
Description: SB-peptide offers the scrambled version of PADRE peptide. AAATLWKAAKFVA can be used as a negative control of PADRE peptide studies.SB-peptide offers also PADRE peptide (see section PADRE peptide).PADRE peptide: Pan HLA DR-binding epitope is a universal peptide that activates antigen specific-CD4+ T cells which can be used as an agonist adjuvant in immunotherapeutic vaccine development. Pan HLA DR-binding epitope has been proposed as a carrier epitope suitable for use in the development of synthetic and recombinant vaccines. It has been demonstrated that PADRE may be an universal approach to control tumor cells. Moreover, PADRE is also used in research about an immunosense approach to develop a base for development of vaccines against toxoplasmosis to protect person with HLA-A*03 type. Pan HLA DR-binding epitope can be also used as tool to study the autoreactive T cell response. |
||
Scrambled 10Panx |
||
| A2701-1 | 1 mg | EUR 40 |
|
Description: Panx-1 mimetic inhibitory peptide, blocks pannexin-1 gap junctions |
||
Scrambled 10Panx |
||
| A2701-10 | 10 mg | EUR 144 |
|
Description: Panx-1 mimetic inhibitory peptide, blocks pannexin-1 gap junctions |
||
Scrambled 10Panx |
||
| A2701-25 | 25 mg | EUR 320 |
|
Description: Panx-1 mimetic inhibitory peptide, blocks pannexin-1 gap junctions |
||
Scrambled 10Panx |
||
| A2701-5 | 5 mg | EUR 80 |
|
Description: Panx-1 mimetic inhibitory peptide, blocks pannexin-1 gap junctions |
||
Scrambled 10Panx |
||
| MBS3840702-10mg | 10mg | EUR 235 |
Scrambled 10Panx |
||
| MBS3840702-25mg | 25mg | EUR 430 |
Scrambled 10Panx |
||
| MBS3840702-5mg | 5mg | EUR 165 |
Scrambled 10Panx |
||
| MBS3840702-5x25mg | 5x25mg | EUR 1920 |
LL-37 (scrambled) |
||
| 4099707.05 | 0.5 mg | EUR 195.51 |
LL-37 (scrambled) |
||
| 4099707.1 | 1 mg | EUR 317.94 |
LL-37 (scrambled) |
||
| H-7886.0500 | 0.5mg | EUR 339.6 |
|
Description: Sum Formula: C205H340N60O53; CAS# [1354065-56-7] net |
||
LL-37 (scrambled) |
||
| H-7886.1000 | 1.0mg | EUR 529.2 |
|
Description: Sum Formula: C205H340N60O53; CAS# [1354065-56-7] net |
||
JAG-1, scrambled |
||
| TP1686-10mg | 10mg | Ask for price |
|
Description: JAG-1, scrambled |
||
JAG-1, scrambled |
||
| TP1686-1g | 1g | Ask for price |
|
Description: JAG-1, scrambled |
||
JAG-1, scrambled |
||
| TP1686-1mg | 1mg | Ask for price |
|
Description: JAG-1, scrambled |
||
JAG-1, scrambled |
||
| TP1686-50mg | 50mg | Ask for price |
|
Description: JAG-1, scrambled |
||
JAG-1, scrambled |
||
| TP1686-5mg | 5mg | Ask for price |
|
Description: JAG-1, scrambled |
||
JAG-1, scrambled |
||
| MBS5789393-INQUIRE | INQUIRE | Ask for price |
Scrambled sgRNA CRISPR/Cas9 All-in-One Lentivector |
||
| K010 | 1.0 ug | EUR 184.8 |
ZIP (SCRAMBLED) Acetate |
||
| T22175L-10mg | 10mg | Ask for price |
|
Description: ZIP (SCRAMBLED) Acetate |
||
ZIP (SCRAMBLED) Acetate |
||
| T22175L-1g | 1g | Ask for price |
|
Description: ZIP (SCRAMBLED) Acetate |
||
ZIP (SCRAMBLED) Acetate |
||
| T22175L-1mg | 1mg | Ask for price |
|
Description: ZIP (SCRAMBLED) Acetate |
||
ZIP (SCRAMBLED) Acetate |
||
| T22175L-50mg | 50mg | Ask for price |
|
Description: ZIP (SCRAMBLED) Acetate |
||
ZIP (SCRAMBLED) Acetate |
||
| T22175L-5mg | 5mg | Ask for price |
|
Description: ZIP (SCRAMBLED) Acetate |
||
ZIP (SCRAMBLED) Acetate |
||
| MBS5773250-1mg | 1mg | EUR 190 |
ZIP (SCRAMBLED) Acetate |
||
| MBS5773250-2mg | 2mg | EUR 235 |
ZIP (SCRAMBLED) Acetate |
||
| MBS5773250-5mg | 5(mg | EUR 300 |
Scrambled TRAP Fragment |
||
| 5-01910 | 4 x 5mg | Ask for price |
Scrambled TRAP Fragment |
||
| T38743-10mg | 10mg | Ask for price |
|
Description: Scrambled TRAP Fragment |
||
Scrambled TRAP Fragment |
||
| T38743-1g | 1g | Ask for price |
|
Description: Scrambled TRAP Fragment |
||
Scrambled TRAP Fragment |
||
| T38743-1mg | 1mg | Ask for price |
|
Description: Scrambled TRAP Fragment |
||
Scrambled TRAP Fragment |
||
| T38743-50mg | 50mg | Ask for price |
|
Description: Scrambled TRAP Fragment |
||
Scrambled TRAP Fragment |
||
| T38743-5mg | 5mg | Ask for price |
|
Description: Scrambled TRAP Fragment |
||
Scrambled TRAP Fragment |
||
| MBS5799340-5mg | 5(mg | EUR 915 |
Scrambled TRAP Fragment |
||
| MBS5799340-5x5mg | 5x5(mg | EUR 3970 |
Scrambled TRAP Fragment |
||
| MBS8247030-10mg | 10mg | EUR 560 |
Scrambled TRAP Fragment |
||
| MBS8247030-1mg | 1mg | EUR 225 |
Scrambled TRAP Fragment |
||
| MBS8247030-5mg | 5mg | EUR 400 |
Scrambled TRAP Fragment |
||
| MBS8247030-5x10mg | 5x10mg | EUR 2435 |
OVA 257-264 scrambled |
||
| SB073 | 1 | EUR 81.81 |
|
Description: SB-peptide offers the scrambled version of OVA 257-264. FILKSINE can be used as a negative control of OVA 257-264 studies.SB-peptide offers also OVA 257-264 (see section OVA 257-264).Ovalbumin protein:OVA 257-264 (H-2Kb) is an epitope of interest of the egg white albumen, ovalbumin. Ovalbumin is a glycoprotein that is sufficiently large and complex to be mildly immunogenic. Indeed, it has been demonstrated that Ovalbumin contains B-cell epitopes which are recognized by specific IgE antibodies and CD4 T cell epitopes restricted by the MHC I-Ad molecule in mice and by HLA-D molecule in human.Applications of OVA 257-264:OVA 257-264 is used to stimulate T cells in PBMCs and to quantify peptide epitope specificity and IFN-γ releasing effector cells by ELISPOT assay. OVA 257-264 is also used to test new adjuvant in immunotherapeutic vaccine development. OVA 257-264 can form a stable hydrogel and stimulate a immune response. This reaction seems to be linked with OVA 257-264 property to self-assemble into a hydrogel. Sequence:C45H74N10013 |
||
Neuropeptide Y (scrambled) |
||
| B7530-1 | 1 mg | EUR 486 |
|
Description: Scrambled Neuropeptide Y (scNPY) was similarly synthesized and contains the same amino acids as NPY, but scNPY is in a random sequence, it was used as a control in the research in NPY [1]. The sequence of scNPY is SKPQRDANREPTRYAIYDYSNPDIELHYLRPAYALG-NH2 [2]. |
||
Neuropeptide Y (scrambled) |
||
| TP2194-10mg | 10mg | Ask for price |
|
Description: Neuropeptide Y (scrambled) |
||
Neuropeptide Y (scrambled) |
||
| TP2194-1g | 1g | Ask for price |
|
Description: Neuropeptide Y (scrambled) |
||
Neuropeptide Y (scrambled) |
||
| TP2194-1mg | 1mg | Ask for price |
|
Description: Neuropeptide Y (scrambled) |
||
Neuropeptide Y (scrambled) |
||
| TP2194-50mg | 50mg | Ask for price |
|
Description: Neuropeptide Y (scrambled) |
||
Neuropeptide Y (scrambled) |
||
| TP2194-5mg | 5mg | Ask for price |
|
Description: Neuropeptide Y (scrambled) |
||
Neuropeptide Y (scrambled) |
||
| MBS5764161-1mg | 1mg | EUR 625 |
Neuropeptide Y (scrambled) |
||
| MBS5764161-5x1mg | 5x1mg | EUR 2655 |
LL-37 scrambled peptide |
||
| HY-P1513 | 1mg | EUR 418.8 |
LL-37 scrambled peptide |
||
| TP1825-10mg | 10mg | Ask for price |
|
Description: LL-37 scrambled peptide |
||
LL-37 scrambled peptide |
||
| TP1825-1g | 1g | Ask for price |
|
Description: LL-37 scrambled peptide |
||
LL-37 scrambled peptide |
||
| TP1825-1mg | 1mg | Ask for price |
|
Description: LL-37 scrambled peptide |
||
LL-37 scrambled peptide |
||
| TP1825-50mg | 50mg | Ask for price |
|
Description: LL-37 scrambled peptide |
||
LL-37 scrambled peptide |
||
| TP1825-5mg | 5mg | Ask for price |
|
Description: LL-37 scrambled peptide |
||
LL-37 scrambled peptide |
||
| MBS5763833-1mg | 1mg | EUR 260 |
LL-37 scrambled peptide |
||
| MBS5763833-5mg | 5mg | EUR 760 |
LL-37 scrambled peptide |
||
| MBS5763833-5x5mg | 5x5mg | EUR 3265 |
MAGE-A p248V9 scrambled |
||
| SB080 | 1 | EUR 93.5 |
|
Description: SB-peptide offers the scrambled version of MAGE-A p248V9. RQYVELPYV can be used as a negative control of MAGE-A p248V9 studies.SB-peptide offers also MAGE-A p248V9 (see section MAGE-A p248V9)).MAGE-A protein:MAGE-A p248V9, also kwon as multi-MAGE-A (YLEYRQVPV) is an epitope of Melanoma Antigen Gene expressed by tumors of different histological types and is a Cancer/Testis Antigens (CTA). Type of MAGE-A expressed in tumors cells varies according to the type of tumor. Targeting epitopes shared by all MAGE-A antigens would be interest in immunotherapy against a broad spectrum of cancers. Applications of MAGE-A p248V9 (multi-MAGE-A) :MAGE-A p248V9 is very useful because it could generate an HLA-A*02:01-restricted CTL response and shared by MAGE-A1,-A2,-A3,-A4,-A6,-A10 and -A12. MAGE-A p248V9 is used to stimulate specific cytotoxic T lymphocytes (CTL) in PBMCs and then to analyze CTL response especially the cytokine production by ELISPOT assay.Sequence : RQYVELPYV |
||
GFP Lentivirus Control |
||
| LTV-300 | 1 vial | EUR 455 |
GFP Lentivirus Control |
||
| MBS168880-1Vial | 1Vial | EUR 645 |
GFP Lentivirus Control |
||
| MBS168880-5x1Vial | 5x1Vial | EUR 2650 |
Human MDM2 siRNA (Scrambled) |
||
| abx941274-150g | 150 µg | EUR 450 |
Human MDM2 siRNA (Scrambled) |
||
| abx941274-300g | 300 µg | EUR 612.5 |
Melan-A (26-35) scrambled |
||
| SB081 | 1 | EUR 64.28 |
|
Description: SB-peptide offers the scrambled version of Melan-A/MART-1 (26-35). AIEIAGGLTV can be used as a negative control of Melan-A/MART-1 (26-35) studies.SB-peptide offers also Melan-A/MART-1 (26-35) (see section Melan-A/MART-1 (26-35)).Native Melan-A (26-35) decapepetide derives from the melanocyte lineage-specific protein Melan-A/MART-1, which is expressed in almost 75-100% of primary and metastatic melanomas1.The region 26-35 of Melan-A protein acts as an antigenic peptide that is recognized by CD8+ tumor-reactive cytolytic T lymphocytes (CTLs) for designing antigen-specific cancer vaccines1. It has been shown that CD8+ Melan-A-specific CTLs isolated from melanoma patients efficiently lyse the Melan-A-expressing HLA-A*0201+ melanoma cell line. However, CTLs preferentially recognize the Melan-A (26-35) peptide as compared with the Melan-A (27-35) peptide1. Moreover, the Melan-A (26-35) A27L analog (ELAGIGILTV) has a higher binding affinity to HLA-A*0201 than the native Melan-A (26-35) peptide (EAAGIGILTV), and consequently displays more potent antigenicity and immunogenicity1.It has been reported that the concentration of Melan-A (26-35) A27L analog required to obtain 50% of maximal antigenic activity (EC50) is 0.01nM, whereas that of the native Melan-A (26-35) peptide is 0.25nM1. Therefore, the relative activity of Melan-A (26-35) A27L analog is 25 fold higher than that of the native Melan-A (26-35) peptide. Furthermore, functional competition assay has shown that the concentration of Melan-A (26-35) A27L analog required to achieve 50% inhibition (IC50) of tumor lysis is 2nM, which is 10 fold lower than that of the native Melan-A (26-35) peptide1. Regarding peptide stability in human serum, the half-lifes (t1/2) of the native Melan-A (26-35) peptide and the A27L analog are quite similar (45 and 40min, respectively) as measured by HPLC-ESI-MS, but much higher than that of the Melan-A (27-35) nonapeptide (5min)1.Sequence : AIEIAGGLTV |
||
MAGE-A2 (157-166) scrambled |
||
| SB082 | 1 | EUR 93.5 |
|
Description: SB-peptide offers the scrambled version of MAGE-A2 (157-166). VLVYFQEIGL can be used as a negative control of MAGE-A2 (157-166) studies.SB-peptide offers also MAGE-A2 (157-166) (see section MAGE-A2 (157-166)).MAGE-A2 protein: MAGE-A2 (157-166) is an epitope of Melanoma Antigen Gene A2 and is one of the most Cancer-Testis Antigens (CTA) overexpressed in tumors of different histological types, such as prostate cancer. Type of MAGE-A expressed in tumors cells varies according to the type of tumor. The expression of MAGE-A2 causes the proliferation of prostate cancer cells and decreases the chemosensitivity. Applications of MAGE-A2 (157-166):MAGE-A2 (157-166) is used to stimulate specific immune response, cytotoxic T cell response and to analyze the cytokine production in PBMCs by ELISPOT assay. In transgenic mouse, it has been demonstrated that MAGE-A2 (157-166) was capable of eliciting a CTL response presented by HLA-A*02:01 molecules. MAGE-A2 (157-166) has been reported to elicit CTL that could lyse tumor cell expressing both HLA-A*02:01 and MAGE-A2 by stimulation of peripheral blood mononuclear cells (PBMCs) with MAGE-A2 (157-166).Sequence : VLVYFQEIGL |
||
MAGE-A1 (278-286) scrambled |
||
| SB083 | 1 | EUR 93.5 |
|
Description: SB-peptide offers the scrambled version of MAGE-A1 (278-286). ELIVKVYKV can be used as a negative control of MAGE-A1 (278-286) studies.SB-peptide offers also MAGE-A1 (278-286) (see section MAGE-A1 (278-286)).MAGE-A1 protein:MAGE-A1 (278-286) is an epitope of Melanoma Antigen Gene A1 expressed by tumors of different histological types such as on the surface of breast carcinoma cell and is a Cancer/Testis Antigens (CTA). MAGE-A1 is a tumor antigen expressed in 40% of melanoma and contains epitope for binding HLA-A*02:01 molecules and that are recognized by cytotoxic T cells. Applications of MAGE-A1 (278-286): MAGE-A1 (278-286) is used to stimulate specific cytotoxic T cells in PBMCs and to analyze by ELISPOT peptide epitope specificity and cytokine production like IFN-γ. Immunogenicity of MAGE-A1 (278-286) raised the possibility of developing anticancer immunotherapies or vaccinations. MAGE-A1 is also expressed in lung adenocarcinoma and studies suggest that MAGE-A1 may serve to develop Chimeric Antigen Receptor (CAR) T cell therapy using lentiviral vector and show an encouraging tumor-inhibitory efficacy.Sequence : ELIVKVYKV |
||
Scrambled shRNA Control THP-1 Cell Line (With GFP) -Polyclone |
||
| T9790 | 1x10^6 cells / 1.0 ml | Ask for price |
Human EGFRviii siRNA (Scrambled) |
||
| abx941279-150g | 150 µg | EUR 450 |
Human EGFRviii siRNA (Scrambled) |
||
| abx941279-300g | 300 µg | EUR 612.5 |
Scrambled TRAP Fragment Peptide |
||
| 20-abx265858 |
|
|
Scrambled TRAP Fragment Peptide |
||
| abx265858-200tests | 200 tests | EUR 225 |
Scrambled TRAP Fragment Peptide |
||
| abx265858-500tests | 500 tests | EUR 312.5 |
5-FAM-LL-37 (scrambled) |
||
| 4099708.05 | 0.5 mg | EUR 335.9 |
5-FAM-LL-37 (scrambled) |
||
| 4099708.1 | 1 mg | EUR 577.5 |
5-FAM-LL-37 (scrambled) |
||
| H-7888.0500 | 0.5mg | EUR 559.2 |
|
Description: Sum Formula: C226H350N60O59; CAS# [2022972-73-0] net |
||
5-FAM-LL-37 (scrambled) |
||
| H-7888.1000 | 1.0mg | EUR 931.2 |
|
Description: Sum Formula: C226H350N60O59; CAS# [2022972-73-0] net |
||
AR-RFP (GFP) Lentivirus |
||
| LVP913-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express RFP reporter under the minimal promoter contains 4 tandem repeats of Androgen Response Element (ARE). This lentivirus also contain the GFP selection marker under the consitutive RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||
AR-Luc (GFP) Lentivirus |
||
| LVP914-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express Firefly luciferase reporter under the minimal promoter contains 4 tandem repeats of Androgen Response Element (ARE). This lentivirus also contain the GFP selection marker under the consitutiveRSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||
G_RE-RFP (GFP) Lentivirus |
||
| LVP950-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express RFP reporter under a minimal promoter embedded 4 tandem repeats of glucocorticoid response element (G-RE). This lentivirus also contain the GFP selection marker under the consitutive RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||
G_RE-Luc (GFP) Lentivirus |
||
| LVP951-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express Firefly luciferase reporter under a minimal promoter embedded 4 tandem repeats of glucocorticoid response element (G-RE). This lentivirus also contain the GFP selection marker under the consitutiveRSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||
H_RE-RFP (GFP) Lentivirus |
||
| LVP970-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express RFP reporter under a minimal promoter that embedded 6 tandem repeats of hypoxia transcriptional response element (H-RE). This lentivirus also contain the GFP selection marker under the consitutive RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||
H_RE-Luc (GFP) Lentivirus |
||
| LVP971-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express Firefly luciferase reporter under a minimal promoter that embedded 6 tandem repeats of hypoxia transcriptional response element (H-RE). This lentivirus also contain the GFP selection marker under the consitutiveRSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||
ER-RFP (GFP) Lentivirus |
||
| LVP974-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express RFP reporter under a minimal promoter that embedded 4 tandem repeats of estrogen receptor response element (ER-RE). This lentivirus also contain the GFP selection marker under the consitutive RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||
ER-Luc (GFP) Lentivirus |
||
| LVP975-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express Firefly luciferase reporter under a minimal promoter that embedded 4 tandem repeats of estrogen receptor response element (ER-RE). This lentivirus also contain the GFP selection marker under the consitutiveRSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||
MB-RFP (GFP) Lentivirus |
||
| LVP1022-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express RFP reporter under human Myoglobin 's promoter which only expressed in muscle, predominantly in cardiac and skeletal myocytes. This lentivirus also contain the GFP selection marker under the consitutive RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||
MB-Luc (GFP) Lentivirus |
||
| LVP1023-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express Firefly luciferase reporter under human Myoglobin 's promoter which only expressed in muscle, predominantly in cardiac and skeletal myocytes. This lentivirus also contain the GFP selection marker under the consitutiveRSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||
HE4-RFP (GFP) Lentivirus |
||
| LVP1042-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express RFP reporter under human HE4's promoter which is overexpressed in ovarian cancer cells. This lentivirus also contain the GFP selection marker under the consitutive RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||
HE4-Luc (GFP) Lentivirus |
||
| LVP1043-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express Firefly luciferase reporter under human HE4's promoter which is overexpressed in ovarian cancer cells. This lentivirus also contain the GFP selection marker under the consitutiveRSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||
PSA-RFP (GFP) Lentivirus |
||
| LVP1046-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express RFP reporter under human PSA's promoter which expressed in normal prostate epithelium and prostate cancers. This lentivirus also contain the GFP selection marker under the consitutive RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||
PSA-Luc (GFP) Lentivirus |
||
| LVP1047-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express Firefly luciferase reporter under human PSA's promoter which expressed in normal prostate epithelium and prostate cancers. This lentivirus also contain the GFP selection marker under the consitutiveRSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||
AR-Rluc (GFP) Lentivirus |
||
| LVP915-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express Renilla luciferase reporter under the minimal promoter contains 4 tandem repeats of Androgen Response Element (ARE). This lentivirus also contain the GFP selection marker under the consitutive RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||
Gli-RFP (GFP) Lentivirus |
||
| LVP946-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express RFP reporter under a minimal promoter embeded 8 tandem repeats of Gli responsive element (hedgehog pathway). This lentivirus also contain the GFP selection marker under the consitutive RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||
Gli-Luc (GFP) Lentivirus |
||
| LVP947-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express Firefly luciferase reporter under a minimal promoter embeded 8 tandem repeats of Gli responsive element (hedgehog pathway). This lentivirus also contain the GFP selection marker under the consitutiveRSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||
G_RE-Rluc (GFP) Lentivirus |
||
| LVP952-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express Renilla luciferase reporter under a minimal promoter embedded 4 tandem repeats of glucocorticoid response element (G-RE). This lentivirus also contain the GFP selection marker under the consitutive RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||
AP1-RFP (GFP) Lentivirus |
||
| LVP954-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express RFP reporter under a minimal promoter that embedded 8 tandem repeats of AP1 Responsive Element (AP1-RE) . This lentivirus also contain the GFP selection marker under the consitutive RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||
AP1-Luc (GFP) Lentivirus |
||
| LVP955-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express Firefly luciferase reporter under a minimal promoter that embedded 8 tandem repeats of AP1 Responsive Element (AP1-RE) . This lentivirus also contain the GFP selection marker under the consitutiveRSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||
SRE-RFP (GFP) Lentivirus |
||
| LVP958-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express RFP reporter under a minimal promoter that embedded 4 tandem repeats of serum response element (SRE) . This lentivirus also contain the GFP selection marker under the consitutive RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||
SRE-Luc (GFP) Lentivirus |
||
| LVP959-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express Firefly luciferase reporter under a minimal promoter that embedded 4 tandem repeats of serum response element (SRE) . This lentivirus also contain the GFP selection marker under the consitutiveRSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||
RBP_JK-RFP (GFP) Lentivirus |
||
| LVP962-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express RFP reporter under a minimal promoter that embedded 4 tandem repeats of RBP-JK transcriptional responsive element (RBP-JK TRE). This lentivirus also contain the GFP selection marker under the consitutive RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||
RBP_JK-Luc (GFP) Lentivirus |
||
| LVP963-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express Firefly luciferase reporter under a minimal promoter that embedded 4 tandem repeats of RBP-JK transcriptional responsive element (RBP-JK TRE). This lentivirus also contain the GFP selection marker under the consitutiveRSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||
H_RE-Rluc (GFP) Lentivirus |
||
| LVP972-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express Renilla luciferase reporter under a minimal promoter that embedded 6 tandem repeats of hypoxia transcriptional response element (H-RE). This lentivirus also contain the GFP selection marker under the consitutive RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||
ER-Rluc (GFP) Lentivirus |
||
| LVP976-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express Renilla luciferase reporter under a minimal promoter that embedded 4 tandem repeats of estrogen receptor response element (ER-RE). This lentivirus also contain the GFP selection marker under the consitutive RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||
P53-RFP (GFP) Lentivirus |
||
| LVP978-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express RFP reporter under a minimal promoter that embedded with optimized tandem repeats of a few most potent P53 transcriptional response element. This lentivirus also contain the GFP selection marker under the consitutive RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||
P53-Luc (GFP) Lentivirus |
||
| LVP979-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express Firefly luciferase reporter under a minimal promoter that embedded with optimized tandem repeats of a few most potent P53 transcriptional response element. This lentivirus also contain the GFP selection marker under the consitutiveRSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||
ARE-RFP (GFP) Lentivirus |
||
| LVP982-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express RFP reporter under a minimal promoter that embedded 4 tandem repeats of antioxidant response element (ARE). This lentivirus also contain the GFP selection marker under the consitutive RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||
ARE-Luc (GFP) Lentivirus |
||
| LVP983-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express Firefly luciferase reporter under a minimal promoter that embedded 4 tandem repeats of antioxidant response element (ARE). This lentivirus also contain the GFP selection marker under the consitutiveRSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||
B29-RFP (GFP) Lentivirus |
||
| LVP994-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express RFP reporter under a human Immunoglobulin gene's promoter which demonstrates B-cell specific expression. This lentivirus also contain the GFP selection marker under the consitutive RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||
B29-Luc (GFP) Lentivirus |
||
| LVP995-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express Firefly luciferase reporter under a human Immunoglobulin gene's promoter which demonstrates B-cell specific expression. This lentivirus also contain the GFP selection marker under the consitutiveRSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||
MB-Rluc (GFP) Lentivirus |
||
| LVP1024-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express Renilla luciferase reporter under human Myoglobin 's promoter which only expressed in muscle, predominantly in cardiac and skeletal myocytes. This lentivirus also contain the GFP selection marker under the consitutive RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||
SPB-RFP (GFP) Lentivirus |
||
| LVP1026-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express RFP reporter under human Surfactant protein B's promoter which selectively expressed in bronchiolar and alveolar epithelial cells of the lung. This lentivirus also contain the GFP selection marker under the consitutive RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||
SPB-Luc (GFP) Lentivirus |
||
| LVP1027-G | 1x107 IFU/ml x 200ul | EUR 662.4 |
|
Description: Pre-made lentivirus express Firefly luciferase reporter under human Surfactant protein B's promoter which selectively expressed in bronchiolar and alveolar epithelial cells of the lung. This lentivirus also contain the GFP selection marker under the consitutiveRSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
||